NCT04902040 2026-03-18
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
Phase 1/2 Terminated
Clinical Trials
14 trialsNCT03575793 2026-01-20
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
Big Ten Cancer Research Consortium
Phase 1/2 Completed
NCT05130827 2025-12-24
Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT02812667 2025-11-12
Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)
University of California, San Diego
Phase 1 Completed
NCT05599789 2025-02-18
KeyPemls-004
Peking Union Medical College Hospital
Phase 2 Active not recruiting
NCT05745350 2025-02-11
First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Recruiting
NCT03102606 2024-08-29
Protective-1
BeyondSpring Pharmaceuticals Inc.
Phase 3 Completed
NCT04345900 2024-05-16
Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2
BeyondSpring Pharmaceuticals Inc.
Phase 2 Completed
NCT02504489 2022-09-10
DUBLIN-3
BeyondSpring Pharmaceuticals Inc.
Phase 3 Completed
NCT03294577 2021-01-15
Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia
BeyondSpring Pharmaceuticals Inc.
Phase 3 Unknown
NCT04227990 2020-01-18
Plinabulin iv Solution in Prevention of TAC Induced Neutropenia
BeyondSpring Pharmaceuticals Inc.
Phase 2 Completed
NCT02846792 2019-03-04
Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer
University of Washington
Phase 1/2 Terminated
NCT00630110 2011-08-16
Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer
Nereus Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT00322608 2011-01-10
Study of the Vascular Disrupting Agent NPI-2358 in Patients With Advanced Solid Tumors or Lymphoma
Nereus Pharmaceuticals, Inc.
Phase 1 Completed